Abstract
G protein coupled receptors (GPCRs) are extremely important drug targets and the β-arrestin intracellular scaffolding and adaptor proteins regulate major aspects of their pharmacology. β-arrestin binding to activated, GPCR kinase (GRK)-phosphorylated receptors has the capacity to terminate G protein coupling, internalize the receptors into clathrincoated vesicles and establish a secondary signaling complex independent of G protein signaling. These events appear to be differentially regulated by GRK phosphorylation, ubiquitination and potentially β-arrestin oligomerization, which are likely to be highly receptor and cell-type dependent. The role of β-arrestins in switching from G-protein dependent to independent signaling places them in a pivotal position to dictate the downstream effects of ligand binding. Consequently, we must appreciate the functioning of these molecules as we strive to discover and optimize new GPCR drug therapies for endocrine, metabolic and immune disorders.
Keywords: G protein coupled receptor, GPCR, β-arrestin, endocytosis, internalisation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: G Protein Coupled Receptors as Drug Targets: The Role of β-Arrestins
Volume: 8 Issue: 1
Author(s): Jasmin R. Dromey and Kevin D.G. Pfleger
Affiliation:
Keywords: G protein coupled receptor, GPCR, β-arrestin, endocytosis, internalisation
Abstract: G protein coupled receptors (GPCRs) are extremely important drug targets and the β-arrestin intracellular scaffolding and adaptor proteins regulate major aspects of their pharmacology. β-arrestin binding to activated, GPCR kinase (GRK)-phosphorylated receptors has the capacity to terminate G protein coupling, internalize the receptors into clathrincoated vesicles and establish a secondary signaling complex independent of G protein signaling. These events appear to be differentially regulated by GRK phosphorylation, ubiquitination and potentially β-arrestin oligomerization, which are likely to be highly receptor and cell-type dependent. The role of β-arrestins in switching from G-protein dependent to independent signaling places them in a pivotal position to dictate the downstream effects of ligand binding. Consequently, we must appreciate the functioning of these molecules as we strive to discover and optimize new GPCR drug therapies for endocrine, metabolic and immune disorders.
Export Options
About this article
Cite this article as:
Dromey R. Jasmin and Pfleger D.G. Kevin, G Protein Coupled Receptors as Drug Targets: The Role of β-Arrestins, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/187153008783928352
DOI https://dx.doi.org/10.2174/187153008783928352 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II) (Supplementry Table)
Current Cardiology Reviews Infective Endocarditis Complicating Hypertrophic Obstructive Cardiomyopathy: Is Antibiotic Prophylaxis Really Unnecessary?
Current Cardiology Reviews Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Evaluation of Early Regenerative Processes in a Preclinical Pig Model of Acute Kidney Injury
Current Molecular Medicine The Relationship Between Cleft Lip, Maxillary Hypoplasia, Hypoxia and Phenytoin
Current Pharmaceutical Design Plant Defensins and Defensin-Like Peptides - Biological Activities and Biotechnological Applications
Current Pharmaceutical Design Nano-Tetrandrine Efficiently Inhibits the Proliferation and Induces the Apoptosis of Hep2 Cells through a Mitochondrial Signaling Pathway
Current Signal Transduction Therapy Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Tipping the Balance Between Life and Death: Targeting Histone Acetylation for Cancer Therapy
Drug Delivery Letters Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry Apoptosis and Autophagy Induction As Mechanism of Cancer Prevention by Naturally Occurring Dietary Agents
Current Drug Targets Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell Death in Mammalian Development
Current Pharmaceutical Design